MX2017014446A - Regulacion de expresion genica mediada por nucleasa. - Google Patents
Regulacion de expresion genica mediada por nucleasa.Info
- Publication number
- MX2017014446A MX2017014446A MX2017014446A MX2017014446A MX2017014446A MX 2017014446 A MX2017014446 A MX 2017014446A MX 2017014446 A MX2017014446 A MX 2017014446A MX 2017014446 A MX2017014446 A MX 2017014446A MX 2017014446 A MX2017014446 A MX 2017014446A
- Authority
- MX
- Mexico
- Prior art keywords
- nuclease
- gene expression
- mediated regulation
- genome
- mediated
- Prior art date
Links
- 101710163270 Nuclease Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000014493 regulation of gene expression Effects 0.000 title 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente descripción se encuentra en el campo de la modificación del genoma, particularmente la modificación dirigida del genoma de una célula hematopoyética.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160396P | 2015-05-12 | 2015-05-12 | |
US201662303595P | 2016-03-04 | 2016-03-04 | |
PCT/US2016/032049 WO2016183298A2 (en) | 2015-05-12 | 2016-05-12 | Nuclease-mediated regulation of gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017014446A true MX2017014446A (es) | 2018-06-13 |
Family
ID=57249092
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017014446A MX2017014446A (es) | 2015-05-12 | 2016-05-12 | Regulacion de expresion genica mediada por nucleasa. |
MX2021005226A MX2021005226A (es) | 2015-05-12 | 2017-11-10 | Regulacion de expresion genica mediada por nucleasa. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005226A MX2021005226A (es) | 2015-05-12 | 2017-11-10 | Regulacion de expresion genica mediada por nucleasa. |
Country Status (17)
Country | Link |
---|---|
US (2) | US10808020B2 (es) |
EP (1) | EP3294866A4 (es) |
JP (2) | JP6873917B2 (es) |
KR (1) | KR20170141217A (es) |
AU (2) | AU2016261927B2 (es) |
BR (1) | BR112017024115A2 (es) |
CA (1) | CA2984013A1 (es) |
CL (1) | CL2017002843A1 (es) |
CO (1) | CO2017012026A2 (es) |
HK (1) | HK1251011A1 (es) |
IL (3) | IL284707B2 (es) |
MX (2) | MX2017014446A (es) |
PH (1) | PH12017502026A1 (es) |
SA (1) | SA517390307B1 (es) |
SG (1) | SG10202112057QA (es) |
WO (1) | WO2016183298A2 (es) |
ZA (1) | ZA201707016B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
SI3068881T1 (sl) * | 2013-11-13 | 2019-05-31 | Children's Medical Center Corporation | Z nukleazo posredovano uravnavanje izražanja genov |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
CA2984013A1 (en) * | 2015-05-12 | 2016-11-17 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
JP6853257B2 (ja) | 2015-09-23 | 2021-03-31 | サンガモ セラピューティクス, インコーポレイテッド | Httリプレッサー及びその使用 |
IL310721A (en) | 2015-10-23 | 2024-04-01 | Harvard College | Nucleobase editors and their uses |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
CN110325635B (zh) | 2016-08-24 | 2023-12-26 | 桑格摩生物治疗股份有限公司 | 使用工程化的核酸酶调控基因表达 |
KR102455249B1 (ko) | 2016-08-24 | 2022-10-17 | 상가모 테라퓨틱스, 인코포레이티드 | 가공된 표적 특이적 뉴클레아제 |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
CN110914426A (zh) | 2017-03-23 | 2020-03-24 | 哈佛大学的校长及成员们 | 包含核酸可编程dna结合蛋白的核碱基编辑器 |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
AU2018352592A1 (en) | 2017-10-16 | 2020-06-04 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
CN111629747A (zh) * | 2017-12-05 | 2020-09-04 | 沃泰克斯药物股份有限公司 | Crispr-cas9修饰的cd34+人血色素干细胞和祖细胞及其用途 |
WO2019150196A1 (en) | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
KR20210049124A (ko) | 2018-08-23 | 2021-05-04 | 상가모 테라퓨틱스, 인코포레이티드 | 조작된 표적 특이적 염기 편집기 |
JP2022517783A (ja) | 2019-01-11 | 2022-03-10 | アクイタス セラピューティクス インコーポレイテッド | 活性剤の脂質ナノ粒子送達のための脂質 |
AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
MA55531A (fr) | 2019-04-02 | 2022-02-09 | Sangamo Therapeutics Inc | Procédés pour le traitement de béta-thalassémie |
CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
EP4182297A1 (en) | 2020-07-16 | 2023-05-24 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
CA3200741A1 (en) * | 2020-12-01 | 2022-06-09 | Daniel Zurr | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
KR20240055084A (ko) | 2021-09-13 | 2024-04-26 | 라이프 테크놀로지스 코포레이션 | 유전자 편집 도구 |
CA3237482A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
AU704601B2 (en) | 1994-01-18 | 1999-04-29 | Scripps Research Institute, The | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
USRE45721E1 (en) | 1994-08-20 | 2015-10-06 | Gendaq, Ltd. | Relating to binding proteins for recognition of DNA |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
CA2321938C (en) | 1998-03-02 | 2009-11-24 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
CA2398590C (en) | 2000-02-08 | 2012-08-28 | Sangamo Biosciences, Inc. | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US20050267061A1 (en) | 2004-04-08 | 2005-12-01 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
EP1421177A4 (en) | 2001-08-20 | 2006-06-07 | Scripps Research Inst | ZINC FINGER FASTENING DOMAINS FOR CNN |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
CA2562193A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
WO2006121866A2 (en) | 2005-05-05 | 2006-11-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
DE602007005634D1 (de) | 2006-05-25 | 2010-05-12 | Sangamo Biosciences Inc | Variante foki-spaltungshälften-domänen |
EP2019839B1 (en) | 2006-05-25 | 2011-12-07 | Sangamo BioSciences, Inc. | Methods and compositions for gene inactivation |
DE602008003684D1 (de) | 2007-04-26 | 2011-01-05 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
CN101855231B (zh) | 2007-06-19 | 2014-06-11 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗-反向硫代磷酸类似物的合成和用途 |
CN101883863B (zh) | 2007-09-27 | 2018-01-23 | 桑格摩生物科学股份有限公司 | 生物活性核酸酶的快速体内鉴定 |
JP2011518555A (ja) | 2008-04-14 | 2011-06-30 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的組込みのための線形ドナーコンストラクト |
CA2725773C (en) | 2008-05-28 | 2017-12-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
KR101759586B1 (ko) | 2008-08-22 | 2017-07-19 | 상가모 테라퓨틱스, 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
ES2738980T3 (es) | 2008-09-15 | 2020-01-28 | Childrens Medical Ct Corp | Modulación de BCL11A para el tratamiento de hemoglobinopatías |
CA2745031C (en) | 2008-12-04 | 2018-08-14 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
EP2461819A4 (en) * | 2009-07-28 | 2013-07-31 | Sangamo Biosciences Inc | METHODS AND COMPOSITIONS FOR TREATING TRI-NUCLEOTIDE REPEAT DISORDERS |
CN105255881A (zh) | 2009-07-31 | 2016-01-20 | 埃泽瑞斯公司 | 用于蛋白质表达的具有未修饰和修饰核苷酸的组合的rna |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
AU2011213242B2 (en) | 2010-02-08 | 2015-01-29 | Sangamo Therapeutics, Inc. | Engineered cleavage half-domains |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
BR112012027532A2 (pt) | 2010-04-26 | 2020-10-13 | Sangamo Biosciences, Inc. | edição de genoma de um locus rosa usando nucleases de dedo de zinco. |
PL2566972T3 (pl) | 2010-05-03 | 2020-06-29 | Sangamo Therapeutics, Inc. | Kompozycje do wiązania modułów z motywem palca cynkowego |
WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
CA2993567C (en) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methods and compositions for modification of a t-cell receptor gene |
WO2012094132A1 (en) | 2011-01-05 | 2012-07-12 | Sangamo Biosciences, Inc. | Methods and compositions for gene correction |
AU2012312260B2 (en) | 2011-09-21 | 2017-08-31 | Sangamo Therapeutics, Inc. | Methods and compositions for regulation of transgene expression |
CA3099582A1 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
JP6144691B2 (ja) | 2011-11-16 | 2017-06-07 | サンガモ セラピューティクス, インコーポレイテッド | 修飾されたdna結合タンパク質およびその使用 |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
RU2650819C2 (ru) | 2012-05-07 | 2018-04-17 | Сангамо Терапьютикс, Инк. | Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов |
BR122021002081B1 (pt) | 2012-05-28 | 2022-07-26 | Evogene Ltd | Método para aumentar a produção, taxa de crescimento, biomassa, vigor, teor de óleo, produção de sementes, produção de fibra, qualidade da fibra, eficiência no uso de nitrogênio, e/ou tolerância ao estresse abiótico de uma planta, e, construção de ácido nucleico isolado |
KR102218562B1 (ko) | 2012-08-29 | 2021-02-19 | 상가모 테라퓨틱스, 인코포레이티드 | 유전적 병태를 치료하기 위한 방법 및 조성물 |
CN109554350B (zh) * | 2012-11-27 | 2022-09-23 | 儿童医疗中心有限公司 | 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件 |
JP2016500254A (ja) | 2012-12-05 | 2016-01-12 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 代謝疾患の調節のための方法および組成物 |
CN105683376A (zh) | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
JP6588438B2 (ja) | 2013-08-28 | 2019-10-09 | サンガモ セラピューティクス, インコーポレイテッド | Dna結合ドメインと切断ドメインとを連結するための組成物 |
SI3068881T1 (sl) | 2013-11-13 | 2019-05-31 | Children's Medical Center Corporation | Z nukleazo posredovano uravnavanje izražanja genov |
CN106413760B (zh) | 2014-05-08 | 2020-01-14 | 桑格摩生物科学股份有限公司 | 用于治疗亨廷顿病的方法和组合物 |
WO2016182917A1 (en) * | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
CA2984013A1 (en) * | 2015-05-12 | 2016-11-17 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
BR112018013065A2 (pt) * | 2015-12-28 | 2018-12-11 | Intellia Therapeutics Inc | composições e métodos para o tratamento de hemoglobinopatias |
JP6974349B2 (ja) * | 2016-04-18 | 2021-12-01 | クリスパー セラピューティクス アクチェンゲゼルシャフト | ヘモグロビン異常症の処置のための材料及び方法 |
-
2016
- 2016-05-12 CA CA2984013A patent/CA2984013A1/en active Pending
- 2016-05-12 KR KR1020177032403A patent/KR20170141217A/ko not_active Application Discontinuation
- 2016-05-12 MX MX2017014446A patent/MX2017014446A/es unknown
- 2016-05-12 JP JP2017559044A patent/JP6873917B2/ja active Active
- 2016-05-12 SG SG10202112057QA patent/SG10202112057QA/en unknown
- 2016-05-12 EP EP16793510.5A patent/EP3294866A4/en active Pending
- 2016-05-12 US US15/565,811 patent/US10808020B2/en active Active
- 2016-05-12 IL IL284707A patent/IL284707B2/en unknown
- 2016-05-12 AU AU2016261927A patent/AU2016261927B2/en active Active
- 2016-05-12 WO PCT/US2016/032049 patent/WO2016183298A2/en active Application Filing
- 2016-05-12 BR BR112017024115A patent/BR112017024115A2/pt active Search and Examination
-
2017
- 2017-10-17 ZA ZA2017/07016A patent/ZA201707016B/en unknown
- 2017-10-26 IL IL255288A patent/IL255288B/en unknown
- 2017-11-07 PH PH12017502026A patent/PH12017502026A1/en unknown
- 2017-11-08 SA SA517390307A patent/SA517390307B1/ar unknown
- 2017-11-09 CL CL2017002843A patent/CL2017002843A1/es unknown
- 2017-11-10 MX MX2021005226A patent/MX2021005226A/es unknown
- 2017-11-27 CO CONC2017/0012026A patent/CO2017012026A2/es unknown
-
2018
- 2018-08-13 HK HK18110341.5A patent/HK1251011A1/zh unknown
-
2020
- 2020-09-15 US US17/021,555 patent/US20210024606A1/en not_active Abandoned
-
2021
- 2021-04-21 JP JP2021071881A patent/JP7365374B2/ja active Active
- 2021-10-06 IL IL287033A patent/IL287033A/en unknown
-
2022
- 2022-07-06 AU AU2022204863A patent/AU2022204863A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201707016B (en) | 2019-08-28 |
US20180111975A1 (en) | 2018-04-26 |
SA517390307B1 (ar) | 2021-07-13 |
IL284707B2 (en) | 2024-01-01 |
IL284707B1 (en) | 2023-09-01 |
WO2016183298A3 (en) | 2016-12-29 |
IL255288B (en) | 2021-10-31 |
CO2017012026A2 (es) | 2018-02-28 |
BR112017024115A2 (pt) | 2018-08-07 |
JP7365374B2 (ja) | 2023-10-19 |
EP3294866A2 (en) | 2018-03-21 |
US10808020B2 (en) | 2020-10-20 |
US20210024606A1 (en) | 2021-01-28 |
JP2021106611A (ja) | 2021-07-29 |
IL287033A (en) | 2021-12-01 |
AU2016261927B2 (en) | 2022-04-07 |
PH12017502026A1 (en) | 2018-04-02 |
JP2018516556A (ja) | 2018-06-28 |
AU2022204863A1 (en) | 2022-07-28 |
IL284707A (en) | 2021-08-31 |
AU2016261927A1 (en) | 2017-11-02 |
EP3294866A4 (en) | 2018-12-05 |
CA2984013A1 (en) | 2016-11-17 |
KR20170141217A (ko) | 2017-12-22 |
HK1251011A1 (zh) | 2019-01-18 |
IL255288A0 (en) | 2017-12-31 |
MX2021005226A (es) | 2021-06-18 |
WO2016183298A2 (en) | 2016-11-17 |
JP6873917B2 (ja) | 2021-05-19 |
CL2017002843A1 (es) | 2018-05-25 |
SG10202112057QA (en) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021005226A (es) | Regulacion de expresion genica mediada por nucleasa. | |
PH12019500281A1 (en) | Regulation of gene expression using engineered nucleases | |
CY1121630T1 (el) | Ρυθμιση της εκφρασης γονιδιου σφαιρινης διαμεσολαβουμενη απο νουκλεασες | |
AU2020201465A1 (en) | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing | |
EP3371314A4 (en) | GENOMIC MANIPULATION OF PLURIPOTENTIAL CELLS | |
MY191210A (en) | Novel promoter and uses thereof | |
EP3441468A3 (en) | Delivery methods and compositions for nuclease-mediated genome engineering | |
GB2544001A (en) | Methods for increasing Cas9-mediated engineering efficiency | |
MX2016014235A (es) | Biosintesis microbiana de ergotioneina. | |
MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
MX2022006692A (es) | Variantes de quimosina con propiedades mejoradas de coagulacion de la leche. | |
DOP2022000085A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
MX2018002366A (es) | Variantes de quimosina con propiedades mejoradas. | |
MX2017014890A (es) | Metodos de produccion de acetolactato-descarboxilasa (aldc). | |
MX2018012872A (es) | Composiciones y metodos para mejorar la expresion genetica de pklr. | |
EA201990568A1 (ru) | Регулирование экспрессии генов с использованием сконструированных нуклеаз | |
UA71729U (uk) | Спосіб підвищення біосинтезу антибіотиків моеноміцинового ряду |